Literature DB >> 10211957

Analysis of the glycosylation sites of hepatitis C virus (HCV) glycoprotein E1 and the influence of E1 glycans on the formation of the HCV glycoprotein complex.

J C Meunier, A Fournillier, A Choukhi, A Cahour, L Cocquerel, J Dubuisson, C Wychowski.   

Abstract

The hepatitis C virus (HCV) genome encodes two membrane-associated envelope glycoproteins (E1 and E2), which are released from the viral polyprotein precursor by host signal peptidase cleavages. These glycoproteins interact to form a noncovalent heterodimeric complex, which is retained in the endoplasmic reticulum. HCV glycoproteins, E1 and E2, are heavily modified by N-linked glycosylation. A recent study has revealed that upon partial deglycosylation with endoglycosidase H only four of the five potential glycosylation sites of HCV glycoprotein E1 are utilized. In this work, the unused glycosylation site on the E1 glycoprotein was identified and the influence of N-linked glycosylation on the formation of the HCV glycoprotein complex was studied by expressing a panel of E1 glycosylation mutants in HepG2 cells. Each of the five potential N-linked glycosylation sites, located at amino acid positions 196, 209, 234, 305 and 325, respectively, on the HCV polyprotein, was mutated separately as well as in combination with the other sites. Expression of the mutated E1 proteins in HepG2 cells indicated that the fifth glycosylation site is not used for the addition of N-linked oligosaccharides and the Pro immediately following the sequon (Asn-Trp-Ser) precludes core glycosylation. The effect of each mutation on the formation of noncovalent E1E2 complexes was also analysed. As determined with the use of a conformation-sensitive monoclonal antibody, mutations at positions N2 and N3 had no, or only minor, effects on the assembly of the E1E2 complex, whereas a mutation at position N1 and predominantly at position N4 dramatically reduced the efficiency of the formation of noncovalent E1E2 complexes.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10211957     DOI: 10.1099/0022-1317-80-4-887

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  41 in total

1.  Topological changes in the transmembrane domains of hepatitis C virus envelope glycoproteins.

Authors:  Laurence Cocquerel; Anne Op de Beeck; Michel Lambot; Juliette Roussel; David Delgrange; André Pillez; Czeslaw Wychowski; François Penin; Jean Dubuisson
Journal:  EMBO J       Date:  2002-06-17       Impact factor: 11.598

2.  Oligomerization of hepatitis C virus core protein is crucial for interaction with the cytoplasmic domain of E1 envelope protein.

Authors:  Kousuke Nakai; Toru Okamoto; Tomomi Kimura-Someya; Koji Ishii; Chang Kweng Lim; Hideki Tani; Eiko Matsuo; Takayuki Abe; Yoshio Mori; Tetsuro Suzuki; Tatsuo Miyamura; Jack H Nunberg; Kohji Moriishi; Yoshiharu Matsuura
Journal:  J Virol       Date:  2006-09-13       Impact factor: 5.103

Review 3.  Capitalizing on knowledge of hepatitis C virus neutralizing epitopes for rational vaccine design.

Authors:  Leopold Kong; Kelli N Jackson; Ian A Wilson; Mansun Law
Journal:  Curr Opin Virol       Date:  2015-04-29       Impact factor: 7.090

4.  Induction of hepatitis C virus E1 envelope protein-specific immune response can be enhanced by mutation of N-glycosylation sites.

Authors:  A Fournillier; C Wychowski; D Boucreux; T F Baumert; J C Meunier; D Jacobs; S Muguet; E Depla; G Inchauspé
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

5.  Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG.

Authors:  Michael Logan; John Law; Jason Alexander Ji-Xhin Wong; Darren Hockman; Amir Landi; Chao Chen; Kevin Crawford; Juthika Kundu; Lesley Baldwin; Janelle Johnson; Anita Dahiya; Gerald LaChance; Joseph Marcotrigiano; Mansun Law; Steven Foung; Lorne Tyrrell; Michael Houghton
Journal:  J Virol       Date:  2016-12-16       Impact factor: 5.103

6.  Role of N-linked glycans in the functions of hepatitis C virus envelope glycoproteins.

Authors:  Anne Goffard; Nathalie Callens; Birke Bartosch; Czeslaw Wychowski; François-Loïc Cosset; Claire Montpellier; Jean Dubuisson
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

7.  Molecular cloning and characterization of Izumo1 gene from sheep and cashmere goat reveal alternative splicing.

Authors:  Wan-Jin Xing; Bao-Da Han; Qi Wu; Li Zhao; Xiao-Hong Bao; Shorgan Bou
Journal:  Mol Biol Rep       Date:  2010-10-21       Impact factor: 2.316

Review 8.  Chaperones in hepatitis C virus infection.

Authors:  Ronik Khachatoorian; Samuel W French
Journal:  World J Hepatol       Date:  2016-01-08

9.  Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein.

Authors:  Ania Owsianka; Alexander W Tarr; Vicky S Juttla; Dimitri Lavillette; Birke Bartosch; François-Loïc Cosset; Jonathan K Ball; Arvind H Patel
Journal:  J Virol       Date:  2005-09       Impact factor: 5.103

10.  Hepatitis C virus envelope glycoprotein co-evolutionary dynamics during chronic hepatitis C.

Authors:  Hui Li; Brian J McMahon; Susan McArdle; Dana Bruden; Daniel G Sullivan; Dave Shelton; Heike Deubner; David R Gretch
Journal:  Virology       Date:  2008-03-17       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.